Minireviews
Copyright ©The Author(s) 2021.
World J Transplant. Jun 18, 2021; 11(6): 187-202
Published online Jun 18, 2021. doi: 10.5500/wjt.v11.i6.187
Table 1 Prognostic scoring systems for patients with acute liver failure
Prognostic model/markerParameters includedPredictive valuesRemarks/drawbacks
KCC[25,26]Age, INR, serum bilirubin, icterus-encephalopathy interval, drug toxicityFor NAALF, Pooled Sn and Sp are 68% and 82%, respectively. For AALF, Pooled Sn and are 58.2% and 94.6%, respectivelyMajor limitation is poor sensitivity, only 58% in recent studies (after 2005). Perform better with advanced HE which is a late event. Combining lactate with the KCC improves sensitivity but reduces specificity
MELD score[34,37]Serum bilirubin, serum creatinine and INRFor NAALF, DOR, Sn, and Sp of MELD scores > 30 are 8.42, 76%, and 73%, respectively. For AALF, DOR, Sn, and Sp of MELD scores > 30 are 6.6, 80%, and 53%, respectivelyThe discriminatory cut-offs and predictive values vary across the studies. Laboratory variations in the determination of serum bilirubin, creatinine and INR
Clichy criteria[38]Advanced HE with factor V levels < 20% in patients < 30 years and < 30% in patients ≥ 30 yrFor NAALF, Sn 69%, Sp 50%, PPV 64%, and NPV 55%. For AALF, Sn 75%, Sp 56%, PPV 50%, and NPV 79%Inferior to KCC and MELD in validation studies. Poor Sp and PPV. Factor V level assay is not a routine parameter
Arterial ammonia[51,52]Baseline arterial ammonia > 124 mol/LSn 78.6%, Sp 76.3%, and DA 77.5%Ammonia levels can be influenced by renal impairment, sepsis, bleeding, haemolysis, drugs etc. Not validated at LT centres. Persistent hyperammonemia is better predictor, but decision is delayed[52]
Blood lactate[28]Post-resuscitation arterial lactate cut-off 3.0 mmol/L in AALFSn 76%, Sp 97%, PLR 30, and NLR 0.24Variability in the timing of lactate measurements. Contradictory results with regard to its performance in NAALF
Serum phosphate[43,54]Level of 1.2 mmol/L at 48 to 96 h after acetamenophen overdoseSn 89%, Sp 100%, PPV 100%, and NPV 98%Such results could not be replicated in subsequent studies[43]
Serum Gc globulin[53]A cut-off level of 80 mg/L in the NAALFSn 49%, Sp 90%, PPV 85%, and NPV 43%Poor sensitivity and NPV. Lacks validation studies
Cytokeratin 18-based modification of the MELD[55]CK18 M65, INR, MELD. A baseline cut-off of 53.5 modified MELDSn 81%, Sp 82%, PPV 65%, and NPV 91%Reported to be better than MELD and KCC, but lack validation studies
APACHE II[46]Multiple parameters. APACHE II >15Sn 82% and Sp 98% for AALFNot specific to liver disease. Lacks validation studies. Cumbersome for routine clinical use
SOFA[45]SOFA score of > 6 by 72 h post-acetamenophen overdoseSn 90%, Sp 69%, PPV 42%, and NPV 96% for AALFNot specific to liver disease. Relatively lower specificity and PPV. Difficulties in calculating the neurological component in intubated patients
Monocyte HLA-DR expression[50]Monocyte HLA-DR expression 15% or less in AALFSn 96%, Sp 100%, DA 98%Lacks validation studies. Reduction in monocyte HLA-DR expression was not associated with outcome in NAALF
BiLE score[49]Bilirubin, lactate, and etiologySn 79% and Sp 84%Scores derived from retrospective analysis. No validation study
ALFED model[27]Over 3 d values of arterial ammonia, serum bilirubin, INR, and advanced HEAUROC for ALFED: 0.92. ALFED score of ≥ 4 had a PPV 85% and NPV 87%Needs further validation. Decision will be delayed. Patients died before 3 d were excluded from analysis. Advanced HE is a late feature
ALFSG index[47]Coma grade, INR, serum bilirubin and phosphorus levels, and log(10) M30Sn 85.6% and Sp 64.7%Requires additional laboratory testing and costs for M30. Found better than MELD and KCC, but requires validation studies
Table 2 Problems with prognostic scoring systems in acute liver failure
Sr NoIssuesRemarks
1All available prognostic scoring systems have limited accuracyError of both commission and omission can happen
2Heterogeneity in the studies evaluating prognosis in ALF: Variations in the definitions of ALF, etiologies, & management protocolThe heterogeneity makes it difficult to compare the results between studies and draw a uniform conclusion
3Survival rates of ALF patients on medical treatment have improved but models used are still the old onesReduced performance of old models (e.g., KCC) have been noted in the newer studies compared to the old ones
4Many studies have considered and analyzed transplanted patients as ‘non-survivors’This may falsely elevate the positive predictive value of a prognostic, increasing the risk of unnecessary LT in some patients
5Lack of reproducibility and validation studies for many prognostic scoresA model cannot be implemented in the clinical practise without adequate validation studies
6Dynamic models are better than models based on baseline parameters, but critical time at which decision should be made is not clearA very late decision may results in loss of opportunity to transplant, and very early decision may lead to unnecessary LT
7Many models have included non-ideal parameters, such as factor V, apoptotic markers, monocyte HLA, etcThese markers are not routinely available and their measurement involve additional investigations and cost
8Some prognostic markers, such as serum bilirubin and INR, are subject to laboratory variationsThis may cause error in selection of LT candidates
9Inclusion of advanced HE in some prognostic modelsHE is subjective markers, and advanced HE is usually a late feature of ALF
10Inclusion of CE in prognostic modelsCE is difficult to diagnosed clinically, and a clinically overt CE is usually a late feature
Table 3 Factors associated with poor outcomes of liver transplantation in acute liver failure patients
Ref.CountryPatientsDeterminant of poor outcomes
Barshes et al[67], 2006United Statesn = 1457 Body mass index > or = 30 kg/m2. Serum creatinine > 2.0 mg/Dl. Recipient age > 50 years old. History of life support.
Bernal et al[56], 2009United Kingdomn = 310Age > 45 years old. Vasopressor requirement. Transplantation before 2000. Use of high-risk grafts.
Park et al[88], 2010South Korean = 44 Older age. Higher MELD.
Germani et al[6], 2012Europen = 4903Recipient > 50 yr. Incompatible ABO matching. Donors > 60 yr. Reduced size graft.
Yuan et al[58], 2012Chinan = 20Pre-transplant waiting time > 5 d.
Yamashiki et al[77], 2012Japann = 209 Older age of recipient and donor. Incompatible ABO.
Hoyer et al[89], 2014Germanyn = 57Lowest pH of the recipient before LT. PH ≤ 7.26 have the worst outcome.
Pamecha et al[90], 2019Indian = 61 Postoperative worsening of cerebral edema. Systemic inflammatory response syndrome. Preoperative culture positivity. Longer duration of anhepatic phase.